-
Mashup Score: 0Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects - 2 year(s) ago
Yael Gernez, MD PhD Yael GernezAffiliationsDivision of Allergy, Immunology and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USANiaz Banaei, MD Niaz BanaeiAffiliationsDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USADivision of Infectious…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 11Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases - 2 year(s) ago
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy across all ages. Immunosuppressed patients were excluded from phase III trials with SARS-CoV-2 mRNA vaccines. Aims To fully characterise B-cell and T-cell immune responses…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
#Immunogenicity upon SARS-CoV-2 mRNA vaccine ⬇️ in immune-compromised patients. Testing #rheumatic diseases with and without #DMARDs: Humoral response: 80% / 55% in wo / with DMARDs Cellular response: 77% / 53% in wo / with DMARDs https://t.co/dWeIHQe0mt https://t.co/Usw8FsQB1M
-
-
Mashup Score: 0Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine - BMC Medicine - 2 year(s) ago
Background There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. Our approach was to target the gene encoding the knob-associated histidine-rich protein (KAHRP), which is responsible for the assembly of knob structures at the infected…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A phase 1 trial investigating the safety, infectivity and #immunogenicity of a genetically-attenuated blood-stage #malaria #vaccine Read it here: https://t.co/eGz2s39crf https://t.co/HM3coCTemt
-
-
Mashup Score: 5Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases - 3 year(s) ago
Patients with rheumatic diseases are at increased risk of infectious complications; vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs may reduce the immunogenicity of common vaccines. We will review here available data regarding the effect of these medications on influenza, pneumococcal, herpes zoster, SARS-CoV-2, hepatitis B, human papilloma virus and…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Vaccination is a key component in the care of people with #RMDs This article reviews vaccine #immunogenicity in patients on #DMARD therapy #pneumococcus #herpeszoster #COVID19 #HepB #HPV #Tetanus #yellowfever #influenza https://t.co/OoMb8wpD6i https://t.co/dreFcS1eLI
-
-
Mashup Score: 6Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies - Blood Cancer Journal - 3 year(s) ago
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cutoff for NAb (p < 0.0001). Only 47% of the patients...
Source: Blood Cancer JournalCategories: Infectious Disease, Latest HeadlinesTweet-
Florent Malard & colleagues evaluated the safety and #immunogenicity of BNT162b2 #vaccine in patients with hematological malignancies. #SARS-CoV-2 https://t.co/RIFERhLDQT https://t.co/eRBlPaVmrW
-
-
Mashup Score: 0Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies - Blood Cancer Journal - 3 year(s) ago
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cutoff for NAb (p < 0.0001). Only 47% of the patients...
Source: Blood Cancer JournalCategories: Infectious Disease, Latest HeadlinesTweet-
Florent Malard & colleagues evaluated the safety and #immunogenicity of BNT162b2 #vaccine in patients with hematological malignancies. #SARS-CoV-2 https://t.co/RIFERhLDQT https://t.co/2rmCaqF0YD
-
-
Mashup Score: 0An AAV-based, room-temperature stable, single dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates - 3 year(s) ago
Zabaleta and colleagues report AAVCOVID, an experimental preventative vaccine for COVID-19. AAVCOVID is a vaccine that delivers the SARS-CoV-2 Spike antigen as a gene via an adeno-associated vector. Results demonstrate protection from viral challenge in NHPs, durable immunogenicity, cross-reactivity with emerging variants, scaled production, and room-temperature stability for 1 month.
Source: Cell Host & MicrobeCategories: Infectious Disease, Latest HeadlinesTweet-
AAVCOVID-1, an adeno-associated viral, Spike gene-based vaccine candidate demonstrates potent #immunogenicity following a single #injection and confers complete protection from #SARS-CoV-2 challenge in macaques. Abstract https://t.co/1tMJGJog5i PDF https://t.co/QlT0yyrrzP https://t.co/cwD0cr0pB9
-
-
Mashup Score: 1
In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, U
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
📣New #podcast out on BMJ talk medicine @crichez33 interviews @rheuma_doktorin & Rebecca H Haberman - key authors of @ARD_BMJ papers on the #immunogenicity of anti-SARS-CoV-2 vaccines. https://t.co/udxC8VtdEs 🎧 & subscribe in Apple Podcasts, Google Podcasts, Stitcher Spotify https://t.co/kw27aXHeDe
-
-
Mashup Score: 1Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 - Cell Research - 3 year(s) ago
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and…
Source: Cell ResearchCategories: Infectious Disease, Latest HeadlinesTweet-
An interferon-armed receptor-binding (RBC) domain dimer enhances the #immunogenicity of RBD for sterilizing immunity against SARS-CoV-2, suggests a new paper by Chinese Academy of Sciences researchers. https://t.co/v5c5uwymqJ https://t.co/Vj1zFExqKZ
-
-
Mashup Score: 1
The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
📢NEW RESEARCH: #safety and #immunogenicity of an inactivated #SARSCoV2 #VACCINE in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial Available #openaccess 👇 https://t.co/ut1Bj0CKwa
-
In Press (Free)! #Immunogenicity of a Third #COVID-19 #mRNA #Vaccine #Dose in #PID Patients with #Functional #B- #cell #Defects #JACIPCOVID https://t.co/yfvZj9Wrq7